PERSONALISED DOSING IN MINUTES
THE END OF TRIAL AND ERROR DOSING
Blind to the signals running through their patient's nerves, clinicians often dose neural therapies via trial and error. With current industry methods, it takes 12 months for epilepsy patients with a Vagus Nerve Stimulator to reach their target dose. 1 in 4 will never reach the target dose due to intolerable side effects.
BIOS’s new approach to dosing uses AI and machine learning techniques to efficiently optimise for a variety of neural and physiological biomarkers. Personalised dosing of neural therapies reduces side effects and improves clinical consistency.
BIOS NeuroTune - our ML-powered dosing co-pilot - personalises neuromodulation device settings in under ten minutes. Our algorithms dynamically model a patient or subject's neural and physiological responses to stimulations and suggest personalised parameters. By visualising each patient’s responses, BIOS NeuroTune gives clinicians confidence that they are selecting the best settings for each patient.
For researchers, BIOS NeuroTune accelerates therapy discovery by assessing thousands of unique stimulations in a single trial–an order of magnitude improvement compared to most pre-clinical trials.
BIOS is now making BIOS NeuroTune available to select clinical and preclinical partners.
EXPLORE PERSONALISED DOSING
BIOS is opening up a new dimension of personalised neural data. As part of our goal to make this ecosystem open, standards-driven, and ethical, we have released a number of tools, papers, and datasets in collaboration with our academic partners.
Explore sample dose response curves with our VNS calibrator simulation, created as part of the NIH SPARC (Stimulating Peripheral Activity to Relieve Conditions) program.
The simulator uses real data collected by BIOS’s proprietary data acquisition system.
To read more about BIOS’s dosing optimisation techniques, read a pre-print version of our paper ”Online Bayesian Optimization of Nerve Stimulation,” (Wernisch 2023).
To read more about how we use our platform to map neural and physiological responses to stimulations, read a pre-print version of our paper “Using Neural Biomarkers to Personalize Dosing of Vagus Nerve Stimulation” (Berthon 2023).